September 5-8, 2017

Boston, MA

Speakers

Confirmed Speakers so far:

  • André Choulika, CEO, Cellectis
  • Tony Polverino, CSO, Kite Pharma
  • Paul Rennert, President & CSO, Aleta Biotherapeutics
  • James Noble, CEO, Adaptimmune
  • Geoff Hodge, CTO, Unum Therapeutics
  • Peter Emtage, CSO, Cell Design Labs
  • Laurence Cooper, CEO, ZIOPHARM Oncology
  • Steffen Walter, CSO, Immatics
  • Samik Basu, Director, Translational Sciences, Adaptimmune
  • Simon Lacey, Director, Translational & Correlative Studies Laboratory, University of Pennsylvania
  • Rodney Rietze, Lead, cGMP Process Automation, Novartis
  • Julianne Smith, VP Translational Sciences, Cellectis
  • Larry Corey, President & Director Emeritus, Fred Hutchinson Cancer Research Center
  • Yangbing Zhao, Director, T Cell Engineering Laboratory , University of Pennsylvania
  • Helen Tayton-Martin, COO, Adaptimmune
  • Shawn Foley, Attorney, Intellectual Property, Burns & Levinson
  • Sadik Kassim, Vice President, Head, Development, Mustang Bio
  • David Sourdive, EVP, Corporate Development, Cellectis
  • David Lebwohl, SVP & Exec Global Program Head, CART GPT, Oncology Global Development, Novartis
  • Philip Gregory, CSO, bluebird bio
  • Jennifer Brogdon, Director, Exploratory Immuno-Oncology, Novartis
  • Ulrik Nielson, CEO, Torque Therapeutics
  • Bruce Levine, Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania
  • Kristin Baird, Medical Officer, Division of Clinical Evaluation, Tissue & Gene Therapies, CBER, FDA
  • Dalia Mahmoud, Executive Director, Pricing & Market Access, Celgene
  • Arie Belldegrun, Chairman and CEO, Founder, Kite Pharma
  • Lei Xiao, Founder, President & CSO, Innovative Cellular Therapeutics
  • Michael Blackton, Vice President, Quality Affairs, CMC, Adaptimmune
  • Jeffrey Chalmers, Professor, Chemical & Biomolecular Engineering, Ohio State University
  • Devon Shedlock, Senior Director, Immuno-Oncology, Poseida Therapeutics
  • Isabelle Rivière, Director, Michael G. Harris Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  • Travis Young, Principal Investigator, CALIBR
  • Thomas Duensing, Chief Technology Officer, IntelliCyt
  • Boro Dropulić, Chief Science Officer, Lentigen Technology, A Miltenyi Biotec Company
  • Jeffrey Borenstein, Laboratory Technical Staff, Draper Laboratories
  • Jenna Balestrini, Senior Member Technical Staff, Draper Laboratories
  • Mark Sawicki, Chief Commercial Officer, Cryoport
  • Claudia Zylberberg, CEO, Akron Biotech
  • Rohit Duggal, Senior Director, Cellular Therapy, Sorrento Therapeutics
  • Markus Dangl, Senior Vice President Research & Pre-Clinical Development, Medigene
  • Michael Farwell, Assistant Professor, Radiology, University of Pennsylvania